- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Tumor Suppressor Gene.
Displaying page 1 of 1.
EudraCT Number: 2014-003785-24 | Sponsor Protocol Number: C15-050TRAVEL | Start Date*: 2014-10-02 | |||||||||||
Sponsor Name:Uzsoki Utcai Kórház | |||||||||||||
Full Title: Treatment of pancreatic adenocarcinoma with the combinationof carboplatin and velparib | |||||||||||||
Medical condition: pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004467-36 | Sponsor Protocol Number: SRA737-02 | Start Date*: 2016-04-13 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer | |||||||||||||
Medical condition: Histologically or cytologically proven solid tumours where treatment with gemcitabine plus cisplatin or gemcitabine alone is considered appropriate by the Investigator. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004486-86 | Sponsor Protocol Number: SRA737-01 | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer | |||||||||||||
Medical condition: Patients with histologically or cytologically proven advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000309-21 | Sponsor Protocol Number: UCa-001 | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Inovio Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | |||||||||||||
Medical condition: Locally advanced unresectable or metastatic/recurrent Urothelial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004811-31 | Sponsor Protocol Number: GIMEMA MDS 0205 | Start Date*: 2006-05-16 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO | |||||||||||||
Full Title: An open label, phase II, non randomized, clinical trial of chemotherapy treatment with 5-Azacytidine plus valproic acid and eventually atra for patients diagnosed with Intermediate II and high risk... | |||||||||||||
Medical condition: Intermediate II and high risk Myelodysplastic syndrome MDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002749-23 | Sponsor Protocol Number: AGMT_MM-1/EMN-13 | Start Date*: 2015-01-19 |
Sponsor Name:AGMT gGmbH | ||
Full Title: Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma | ||
Medical condition: refractory and/or relapsed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023584-17 | Sponsor Protocol Number: RAS-AZIC | Start Date*: 2012-08-31 | |||||||||||
Sponsor Name:Universität Leipzig | |||||||||||||
Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent... | |||||||||||||
Medical condition: acute myeloid leukeamia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004842-92 | Sponsor Protocol Number: SECOMBIT | Start Date*: 2016-06-30 | |||||||||||
Sponsor Name:FONDAZIONE MELANOMA ONLUS | |||||||||||||
Full Title: A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... | |||||||||||||
Medical condition: Metastatic melanoma and BRAF mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) DE (Completed) GR (Completed) AT (Ongoing) GB (GB - no longer in EU/EEA) SE (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.